| Literature DB >> 27769033 |
Li-Qiang Han1, Xia Yuan1, Xing-Yu Wu1, Ri-Dong Li1, Bo Xu1, Qing Cheng1, Zhen-Ming Liu1, Tian-Yan Zhou1, Hao-Yun An2, Xin Wang1, Tie-Ming Cheng1, Ze-Mei Ge3, Jing-Rong Cui4, Run-Tao Li5.
Abstract
A novel class of urea-containing peptide boronic acids as proteasome inhibitors was designed by introducing a urea scaffold to replace an amido bond. Compounds were synthesized and their antitumor activities were evaluated. After two rounds of optimizations, the compound I-14 was found to be a potent proteasome inhibitor. Compared with Bortezomib, I-14 showed higher potency against the chymotrypsin-like activity of human 20S proteasome (IC50 < 1 pM), similar potency against four different cancer cell lines (IC50 < 10 nM), and better pharmacokinetic profile. Furthermore, I-14 significantly inhibited tumor growth in Bel7404 mouse xenograft model. The excellent proteasome inhibition by I-14 was rationalized through docking and molecular dynamics studies. Copyright ÂEntities:
Keywords: Anti-tumor activity; Low toxicity; Proteasome inhibitor; Structure-activity relationship; Urea-containing peptide boronic acids
Mesh:
Substances:
Year: 2016 PMID: 27769033 DOI: 10.1016/j.ejmech.2016.10.023
Source DB: PubMed Journal: Eur J Med Chem ISSN: 0223-5234 Impact factor: 6.514